Probiotic compound preparation for improving infantile constipation and application thereof

Abstract

The invention provides a probiotic compound preparation for improving infantile constipation and application of the probiotic compound preparation. The bifidobacterium infantis oral liquid is prepared from the following components in parts by weight: 2 to 3 parts of bifidobacterium infantis, 3 to 4 parts of bifidobacterium animalis Bb-12, 0.5 to 2 parts of bifidobacterium bifidum R0071, 2 to 4 parts of bifidobacterium breve M-16V, 2 to 4 parts of bifidobacterium lactis HN-019, 40 to 50 parts of polydextrose, 1 to 3 parts of glycerol monolaurate, 0.5 to 2 parts of cranberries, 2 to 3 parts of fructus momordicae, 1 to 3 parts of poria cocos and 1 to 3 parts of fructus gardeniae, and all the components are powder. The formulas of the probiotic compound preparation have a synergistic effect, so that the children constipation can be obviously improved, the effective flora in the intestinal tract can be increased, the harmful flora in the intestinal tract can be reduced, the intestinal flora of a child patient can be effectively regulated, the immune function of the child patient can be improved, the effect is good, and no adverse reaction is caused.

Description

Technical Field

[0001] The invention relates to the technical field of probiotic products, and in particular to a probiotic compound preparation for improving constipation in children and an application thereof. Background Art

[0002] Constipation is a common clinical functional gastrointestinal disease. It has become one of the main health problems that plague modern people and seriously affects people's quality of life. Studies have shown that constipation patients generally have slow intestinal motility and intestinal flora disorders. Pediatric constipation is mostly functional constipation, with symptoms such as dry stools, reduced bowel movements and difficulty in defecation, which have adverse effects on the physical and mental health and quality of life of children. Most people generally choose diet therapy to relieve symptoms, such as taking probiotics to improve intestinal flora, enhance small intestinal motility, improve constipation symptoms, and use dietary fiber to prevent and treat constipation, increase moisture and softness in the intestines to promote defecation, but market feedback is not ideal.

[0003] There are also many patents in the prior art that disclose probiotic beverages with different formulas. For example, CN109123295A discloses a probiotic solid beverage and a preparation method thereof. The probiotic solid beverage includes the following raw materials by weight: 25-30 parts of inulin, 5-10 parts of cranberry extract and 1-5 parts of probiotics; wherein the probiotics include Bifidobacterium lactis, Lactobacillus acidophilus, Lactobacillus rhamnosus, Lactobacillus casei, Lactobacillus reuteri, Lactobacillus plantarum, and Bifidobacterium longum; it can reduce the loss of probiotics when passing through the gastrointestinal tract, regulate the stomach, relieve constipation, diarrhea, regulate the body's immune function, regulate blood sugar levels, and especially significantly improve gynecological inflammation, as well as spots, dull skin, and dry hair in women caused by constipation. Another example is CN109619596A discloses a probiotic powder for regulating constipation and a preparation method thereof, which has a certain regulating effect on constipation.

[0004] However, the above probiotic solid beverages are not targeted at pediatric constipation and have limited effects. Based on this, it is very necessary to provide a new probiotic compound preparation for improving constipation. Summary of the invention

[0005] In view of the deficiencies of the prior art, the purpose of the present invention is to provide a probiotic compound preparation for improving constipation in children and its application. The formulas of the probiotic compound preparation have a synergistic effect, which can significantly improve constipation in children, increase the beneficial bacteria in the intestine, reduce the harmful bacteria in the intestine, effectively regulate the intestinal flora of the children, and improve the immune function of the children. The probiotic compound preparation has a good effect on improving constipation in children and has no adverse reactions.

[0006] In order to achieve the above-mentioned object of the invention, the technical solution of the present invention is:

[0007] A probiotic compound preparation for improving constipation in children comprises probiotics and is composed of the following components in parts by weight: 2-3 parts of infant bifidobacterium, 4 parts of animal bifidobacterium Bb-123, 0.5-2 parts of bifidobacterium bifidum R0071, 2-4 parts of bifidobacterium breve M-16V, 2-4 parts of bifidobacterium lactis HN-019, 40-50 parts of polydextrose, 1-3 parts of monolaurin, 0.5-2 parts of cranberry, 2-3 parts of monk fruit, 1-3 parts of poria cocos and 1-3 parts of gardenia, wherein all the above components are solid powders.

[0008] The preferred formula is composed of the following components in parts by weight: 2 parts of infant bifidobacterium, 3 parts of animal bifidobacterium Bb-12, 11 parts of bifidobacterium bifidum R007, 3 parts of bifidobacterium breve M-16V, 3 parts of bifidobacterium lactis HN-019, 45 parts of polydextrose, 2 parts of monolaurin, 1 part of cranberry, 2 parts of monk fruit, 2 parts of poria cocos, and 1 part of gardenia, and all of the above components are solid powders.

[0009] Another preferred formula is composed of the following components in parts by weight: 3 parts of infant Bifidobacterium, 4 parts of animal Bifidobacterium Bb-12, 2 parts of Bifidobacterium bifidum R0071, 4 parts of Bifidobacterium breve M-16V, 4 parts of Bifidobacterium lactis HN-019, 48 parts of polydextrose, 3 parts of lauric acid monoglyceride, 2 parts of cranberry, 3 parts of Momordica grosvenori, 3 parts of Poria cocos, and 2 parts of Gardenia jasminoides, and all of the above components are solid powders.

[0010] Preferably, the powder is a solid powder of 80-100 meshes.

[0011] Preferably, the preparation method of the probiotic compound preparation for improving constipation in children comprises: grinding polydextrose, monolaurin, cranberry, monk fruit, poria cocos, and gardenia into 80-100 mesh fine powder according to the above proportions; then uniformly mixing with Bifidobacterium infantis, Bifidobacterium animalis Bb-12, Bifidobacterium bifidum R0071, Bifidobacterium breve M-16V, and Bifidobacterium lactis HN-019, passing through an 80-100 mesh sieve, and mixing according to the above proportions to obtain.

[0012] The present invention also provides the use of the probiotic compound preparation in preparing health products, foods or medicines for treating and improving constipation in children.

[0013] The present invention is further explained and described below.

[0014] Monolaurin: It is a lipophilic nonionic surfactant that exists naturally in breast milk, coconut oil and American palmetto. It can also be obtained by direct esterification of natural lauric acid and glycerol. It is also a safe, efficient and broad-spectrum antibacterial agent with emulsifying, antibacterial and antiviral properties.

[0015] Polydextrose: A natural prebiotic, a water-soluble polysaccharide that has a good effect in strengthening the body, lowering blood lipids, anti-oxidation, and promoting intestinal health.

[0016] Cranberry: Contains proanthocyanidins, ellagic acid, phenolic acid, resveratrol and other substances. It has antibacterial effects, can inhibit the infection of Helicobacter pylori, prevent urinary tract infections, and has antioxidant effects. It can fight against lipid peroxidation in unsaturated fatty acids in biological membranes, protect the structure and function of cell membranes, and play a role in preventing cardiovascular diseases.

[0017] Luo Han Guo: It is rich in nutrients such as glucose, fructose and various vitamins. It has the effects and functions of clearing heat and moistening the lungs, relieving sore throat and opening voice, moistening the intestines and promoting bowel movements, enhancing immunity and anti-oxidation.

[0018] Poria: Contains polysaccharides, diterpenes, triterpenes, sterols, phosphates and other chemical components, and shows good biological activity. It has anti-tumor, immune regulation, effects on diabetes and related complications, lipid metabolism regulation, kidney protection, heart protection, liver protection, etc.

[0019] Gardenia: The main ingredients include cyclopentane terpenes, flavonoids, organic acid esters, etc. Modern research has found that gardenia has pharmacological effects such as antipyretic, anti-inflammatory, sedative, antihypertensive, and lipid-regulating. It is clinically used for depression, acute liver damage, eczema, etc.

[0020] Compared with the prior art, the advantages of the present invention are:

[0021] 1. The preparation method of the composition of the present invention is simple and the clinical experimental effect is highly effective.

[0022] 2. Compared with the formula of the comparative example, the composition of the present invention has a stronger synergistic effect and better therapeutic effect.

[0023] 3. Pharmacodynamic research data proves that the composition of the present invention has a significant improvement effect on constipation model mice; it can accelerate the propulsion rate of ink in the small intestine of constipated mice, shorten the time for mice to excrete the first black stool, increase the number of stools excreted within 8 hours and the water content of feces, and long-term intervention is more conducive to the improvement of defecation conditions, and has no adverse reaction to the growth of mice.

[0024] 4. Clinical use effects have proved that after treatment with the composition of the present invention, the patients' Enterobacteriaceae, yeasts and Staphylococci were significantly reduced, and Bifidobacteria were significantly increased; CD3+, CD4+ and CD4+ / CD8+ were all significantly increased, and CD8+ was significantly reduced; the treatment of pediatric constipation can effectively regulate the intestinal flora of the children and improve the immune function of the children, and the patients using the composition of the present invention have a high total effective rate of clinical improvement and a low incidence of adverse reactions.

[0025] The detailed structure of the present invention is further described below in conjunction with specific implementation methods. DETAILED DESCRIPTION

[0026] Example 1

[0027] A probiotic compound preparation for improving constipation in children is composed of the following components in parts by weight: 2 parts of infantis bifidobacterium, 3 parts of animal bifidobacterium Bb-12, 11 parts of bifidobacterium bifidum R007, 3 parts of bifidobacterium breve M-16V, 3 parts of bifidobacterium lactis HN-019, 45 parts of polydextrose, 2 parts of monolaurin, 1 part of cranberry, 2 parts of monk fruit, 2 parts of poria cocos, and 1 part of gardenia.

[0028] The preparation method comprises: grinding polydextrose, monolaurin, cranberry, monk fruit, poria cocos and gardenia into 80-mesh fine powder according to the above proportion; then uniformly mixing with infant bifidobacterium, animal bifidobacterium Bb-12, bifidobacterium bifidum R0071, bifidobacterium breve M-16V and bifidobacterium lactis HN-019, passing through an 80-mesh sieve, and mixing according to the above proportion to obtain.

[0029] Comparative Example 1

[0030] A composite probiotic consists of the following components in parts by weight: Bifidobacterium animalis Bb-123, Bifidobacterium breve M-16V 3, Bifidobacterium lactis HN-0193, and polydextrose 45, all of which are solid powders of 80 mesh.

[0031] Comparative Example 2:

[0032] A probiotic complex consists of the following components in parts by weight: 2 parts of infant bifidobacterium, 3 parts of animal bifidobacterium Bb-12, 11 parts of bifidobacterium bifidum R007, 3 parts of bifidobacterium breve M-16V, 3 parts of bifidobacterium lactis HN-019, 45 parts of polydextrose and 1 part of cranberry, wherein all the above components are solid powders of 80 mesh.

[0033] Preparation method: firstly grind polydextrose and cranberry into 80-mesh fine powder according to the above ratio; then add infant bifidobacterium, animal bifidobacterium Bb-12, bifidobacterium bifidum R0071, bifidobacterium breve M-16V, and bifidobacterium lactis HN-019 through an 80-mesh sieve, and mix according to the above ratio to obtain the product.

[0034] Application effect experimental data

[0035] Animal pharmacodynamics experimental data of Example 1, Comparative Example 1 and Comparative Example 2

[0036] Experiment 1: Effects on constipation model mice

[0037] 1. Purpose of the test

[0038] In this experiment, mice were given the combination of Example 1 and Comparative Examples 1 and 2 by gavage to observe the effects of the combination of Example 1 and Comparative Examples 1 and 2 on constipation model mice, providing an experimental basis for clinical application.

[0039] 2. Test materials

[0040] Test substance (test product): the composition of Example 1 and Comparative Example 1 and Comparative Example 2 (Guyitang (Hunan) Health Technology Co., Ltd.), intended clinical dose: 4 g / day; intended clinical route: oral, 1 bag at a time, twice a day, taken with warm water, intended clinical course of treatment: 2 months.

[0041] Main reagents: Name: Loperamide hydrochloride capsules, manufacturer: Shanghai Zhaohui Pharmaceutical Company; Arabic gum, activated carbon powder manufacturer: Sinopharm Chemical Reagent Co., Ltd.;

[0042] Test methods

[0043] 1 Experimental animals: SPF-grade male mice that passed quarantine, with a weight range of 19.3-21.8 g (Hunan Slake Jingda Experimental Animal Co., Ltd.).

[0044] 2. Sample preparation:

[0045] The recommended dose for human gavage is 4 g / day for the clinical use of the composition of Example 1, Comparative Examples 1 and Comparative Examples 2. According to the conversion table of equivalent doses between animal species in Pharmacological Experimental Methodology, fourth edition, compiled by Wei Wei, the body surface area is converted into mice: 4 g / ×0.0026 / 0.02 kg=0.52 g / kg. The volumes are respectively made up to 100 ml with physiological saline and mixed. The temperature is raised to 37°C in a water bath before gavage.

[0046] 3 Animal grouping and treatment: The mice were randomly divided into a blank group, a model group, Example 1, Comparative Example 1 and Comparative Example 2, with 10 mice in each group. The blank group and the model group were gavaged with normal saline, and the Example 1, Comparative Example 1 and Comparative Example 2 groups were gavaged with diluted samples, and gavage was performed once at a fixed time of 9:00 every morning, and the body weight was weighed, and the gavage volume was adjusted in time. The mice were free to drink water and eat. On the 7th and 14th days, loperamide hydrochloride 5 mg / kg was gavaged to induce constipation model mice, and the relevant indicators were measured.

[0047] 4 Determination indicators and methods: 1) Small intestinal ink propulsion rate of mice. Ink propulsion rate determination was performed by gavage of loperamide, a constipation model of mice was established, and the ink propulsion rate of the small intestine within a certain period of time was calculated to determine the gastrointestinal motility function of the model mice. 0.5h after administration of loperamide hydrochloride gel, each group was given ink containing the test sample (containing 5% activated carbon powder and 10% gum arabic), and the blank control group and model control group mice were gavaged with ink. Immediately after 25min, the animals were killed by dislocation of the cervical vertebrae, the abdominal cavity was opened to separate the mesentery, and the intestinal tube from the upper end to the pylorus and the lower end to the ileocecal part was cut, placed on a tray, and gently pulled into a straight line. The length of the intestinal tube was measured as the total length of the small intestine, and the length from the pylorus to the front edge of the ink was the ink propulsion length. The ink propulsion rate was calculated; 2) Defecation time and number of feces of mice. After gavage with ink, the time of the first black stool was recorded, and feces were collected within 8h; 3) Water content of mouse feces. The water content of feces was determined by drying method.

[0048] Data Statistical Analysis

[0049] SPSS 16.0 software was used for statistical analysis, and the experimental data were expressed as mean ± standard deviation. Systematic anatomy and histopathology were judged by qualitative indicators; the measurement data were tested for normality and homogeneity of variance. If normality was met, one-way analysis of variance (ANOVA) was used for statistical analysis, and LSD+Dunnett-t (homogeneous variance) or Tamhane's T2 (unhomogeneous variance) was used for comparative analysis according to the homogeneity of variance; if normality was not met, Kruskal-Wallis test was used, and Mann-Whitney test was used for pairwise comparison analysis; P<0.05 indicated statistical difference or P<0.01 indicated significant statistical difference, and its biological significance was considered during evaluation.

[0050] Table 1 Changes in body weight of mice in each group ( n=10)

[0051]

[0052] The animals were weighed on the 1st, 7th and 14th days after administration. There was no statistically significant difference in the weight of the animals between the composition group of Example 1 and the blank group and Comparative Examples 1 and 2 during the same period, and the weight gain was within the normal growth range, indicating that oral administration of the composition of Example 1 to mice had no significant effect on the weight gain of the mice and had no adverse reaction to the growth of the mice.

[0053] Experiment 2: Effects on the propulsion rate of ink in the small intestine of constipated mice

[0054] After each group of experimental mice was continuously gavaged with the corresponding suspension for 7 and 14 days, the model was established and the small intestinal ink propulsion test was performed. The ink propulsion rate of the intestine of each group of mice is shown in Table 2. As can be seen from Table 2, the ink propulsion rate of the model group was significantly lower than that of the blank group, indicating that the mouse constipation model was established. Compared with the model group, the small intestinal ink propulsion rate of each group was higher, and the difference was significant (P<0.05), indicating that Comparative Example 1, Comparative Example 2 and Example 1 can all promote small intestinal peristalsis, among which the small intestinal ink propulsion rate of Example 1 group was higher than that of Comparative Example 1 and Comparative Example 2, indicating that Example 1 has a better effect, and Example 1 has a significant synergistic effect compared with Comparative Example 1 and Comparative Example 2 groups. The small intestinal propulsion rate of each group after 14 days of intervention was higher than that after 7 days of intervention, indicating that long-term intervention is more conducive to improving defecation conditions.

[0055] Table 2 Effects on the ink propulsion rate in the small intestine of constipated mice

[0056]

[0057] Note: Compared with the blank control group in the same period, "**" indicates P < 0.01, compared with the model control group in the same period, "ΔΔ" indicates P < 0.01, compared with the comparative example 1 in the same period, "#" indicates P < 0.05, "##" indicates P < 0.01, compared with the comparative example 2 in the same period, "▲" indicates P < 0.05.

[0058] After 7 and 14 days of gavage intervention with the corresponding samples, the time of the first black stool, the number of stool particles within 8 hours, the amount of stool and the water content of feces of the constipation model mice were measured respectively, and the results are shown in Table 3. Compared with the blank control group, the time of the first black stool, the number of stool particles and the water content of feces of the model group mice were significantly different, indicating that the constipation mouse model was established. At the same time, the time of the first black stool, the number of stool particles in 8 hours and the water content of feces of the mice in the comparative example 1, the comparative example and the embodiment 1 were significantly better than those in the model group. Compared with the comparative example 1 and the comparative example 2, the effect of the embodiment 1 was the most obvious, indicating that the embodiment 1 promoted intestinal peristalsis and promoted the defecation of mice better, indicating that the efficacy of the embodiment 1 was better, and the synergistic effect of the embodiment 1 was obvious compared with the comparative example 1 and the comparative example 2 groups. The time of the first black stool was shortened, the number of stool particles increased, and the water content of feces increased after the intervention of 14 days compared with the intervention of 7 days, indicating that long-term intervention is more conducive to the improvement of defecation.

[0059] Table 3 Effects on defecation of constipated mice ( n=10)

[0060]

[0061] Note: Compared with the blank control group in the same period, "**" indicates P < 0.01, compared with the model control group in the same period, Δ " indicates P < 0.05," ΔΔ” indicates P<0.01, compared with comparative example 1 of the same period; “#” indicates P<0.05; “##” indicates P<0.01, compared with comparative example 2 of the same period; “▲” indicates P<0.05.

[0062] Clinical analysis data of the composition of Example 1, Comparative Example 1 and Comparative Example 2

[0063] General data: 150 children with constipation were selected according to the standard for observation and randomly divided into Example 1 and a control group. In Example 1, there were 40 male children and 35 female children, aged 2 to 8 years old, with an average age of (5.42±0.95) years old, a course of 1 month to 6 months, and an average of (3.12±0.87) months. There were 38 children in the control group, 37 female children, aged 2 to 8 years old, with an average age of (5.29±0.93) years old, a course of 1 month to 6 months, and an average of (3.07±0.85) months. There was no significant difference in the general data between the two groups of children (P>0.05).

[0064] Treatment method: The children in the control group were treated with oral lactulose oral solution (specification: 60mL: 40.02g), 3 times a day, 10mL each time. The children in Example 1 were given the composition of Example 1, 1 bag at a time, 2g per bag, twice a day; taken with warm water, and both groups of children continued to take the medicine for 8 weeks.

[0065] Diagnostic criteria for constipation: ① Based on the international Rome IV criteria for functional constipation in children;

[0066] Inclusion criteria: ① functional constipation; ② age 2-8 years old;

[0067] Exclusion criteria: ① genetic diseases such as Rett syndrome and 22q13 deletion syndrome; ② infectious diseases; ③ severe liver, kidney, and hematopoietic system diseases; ④ congenital heart disease and other congenital malformations; ⑤ severe allergic constitution.

[0068] The efficacy of constipation is based on the "Standards for Determining the Efficacy of TCM Disease Diagnosis and Efficacy": ① Cured, the number of bowel movements returned to normal, the stool was soft and formed, the bowel movement was smooth, and there were no other discomfort symptoms; ② Significantly effective, bowel movements were once every 1-2 days, soft stools were formed, and the bowel movement was smooth; ③ Effective: bowel movements were once every 2 days, the shape of the stool changed from hard balls to sausage-like, with cracks on the surface, and the difficulty in defecation still existed for a certain period of time; ④ Ineffective: no obvious change in symptoms. Total effective rate = (number of cured cases + number of markedly effective cases + number of effective cases) / total number of cases.

[0069] Observation indicators: Compare the intestinal flora and peripheral blood lymphocyte levels (CD3+, CD4+, CD8+ and CD4+ / CD8+) of the two groups of children before treatment and 8 weeks after treatment; record the occurrence of adverse reactions during the treatment; compare the treatment effects of the two groups of children.

[0070] Table 4 Comparison of disease efficacy between the two groups of patients

[0071]

[0072] Note: Compared with the control group, "*" indicates P < 0.05

[0073] Table 5 Comparison of changes in intestinal flora between the two groups

[0074]

[0075] Note: Compared with the group before treatment, "*" indicates P < 0.05; compared with the control group after treatment, "#" indicates P < 0.05

[0076] Table 6 Comparison of immune function between the two groups

[0077]

[0078] Table 7 Comparison of adverse reactions between the two groups of patients

[0079]

[0080]

[0081] Note: Compared with the control group, "*" indicates P < 0.05

[0082] Clinical analysis data showed that after treatment of the two groups of patients, the levels of Enterobacteriaceae, yeast and Staphylococcus in Example 1 were lower than those in the control group, while Bifidobacterium was higher than that in the control group, and the differences were statistically significant (P<0.05). After treatment, the levels of CD3+, CD4+ and CD4+ / CD8+ in Example 1 were higher than those in the control group, while CD8+ was lower than that in the control group, and the differences were statistically significant (P<0.05). The total effective rate of the Example 1 group was higher than that of the control group, and the difference was statistically significant (P<0.05). The difference in adverse reactions between the two groups was statistically significant (P<0.05). Conclusion: Example 1 can effectively regulate the intestinal flora of children and improve their immune function in the treatment of constipation in children, and the safety and effectiveness of clinical treatment are high.

[0083] Example 2

[0084] A probiotic compound preparation for improving constipation in children is composed of the following components in parts by weight: 3 parts of infant bifidobacterium, 4 parts of animal bifidobacterium Bb-12, 2 parts of bifidobacterium bifidum R0071, 4 parts of bifidobacterium breve M-16V, 4 parts of bifidobacterium lactis HN-019, 48 parts of polydextrose, 3 parts of lauric acid monoglyceride, 2 parts of cranberry, 3 parts of monk fruit, 3 parts of poria cocos, and 2 parts of gardenia, wherein all the above components are solid powders of 80 mesh, and the preparation method is the same as that of Example 1.

[0085] The formula of Example 2 is the same as that of Example 1, the proportions are similar, and the application effect is similar to that of Example 1, which will not be repeated here.

[0086] The above is a specific implementation mode of the present invention, but the protection scope of the present invention is not limited thereto. Any technician familiar with the technical field, within the technical scope disclosed by the present invention, can make equivalent replacements or changes according to the technical solutions and concepts of the present invention, which should be covered by the protection scope of the claims of the present invention.

Claims

1. A probiotic compound preparation for improving constipation in children, comprising probiotics, characterized in that: The invention is composed of the following components in parts by weight: 2-3 parts of infant bifidobacterium, 3-4 parts of animal bifidobacterium Bb-12, 0.5-2 parts of bifidobacterium bifidum R0071, 2-4 parts of bifidobacterium breve M-16V, 2-4 parts of bifidobacterium lactis HN-019, 40-50 parts of polydextrose, 1-3 parts of monolaurin, 0.5-2 parts of cranberry, 2-3 parts of monk fruit, 1-3 parts of poria cocos and 1-3 parts of gardenia, and all the above components are solid powders.

2. The probiotic compound preparation for improving constipation in children according to claim 1, comprising the following components in parts by weight: 2 parts of infant bifidobacterium, 3 parts of animal bifidobacterium Bb-12, 1 part of bifidobacterium bifidum R0071, 3 parts of bifidobacterium breve M-16V, 3 parts of bifidobacterium lactis HN-019, 45 parts of polydextrose, 2 parts of lauric acid monoglyceride, 1 part of cranberry, 2 parts of monk fruit, 2 parts of poria cocos, and 1 part of gardenia, all of which are solid powders.

3. The probiotic compound preparation for improving constipation in children according to claim 1, comprising the following components in parts by weight: 3 parts of infant bifidobacterium, 4 parts of animal bifidobacterium Bb-12, 2 parts of bifidobacterium bifidum R0071, 4 parts of bifidobacterium breve M-16V, 4 parts of bifidobacterium lactis HN-019, 48 parts of polydextrose, 3 parts of lauric acid monoglyceride, 2 parts of cranberry, 3 parts of monk fruit, 3 parts of poria cocos, and 2 parts of gardenia, and all of the above components are solid powders.

4. The probiotic compound preparation for improving constipation in children according to any one of claims 1 to 3, characterized in that: The powder is a solid powder of 80 meshes to 100 meshes.

5. The probiotic compound preparation for improving constipation in children according to any one of claims 1 to 3, characterized in that: The preparation method comprises: grinding polydextrose, monolaurin, cranberry, monk fruit, poria cocos and gardenia into fine powder of 80-100 meshes according to the above proportions; then uniformly mixing with infant bifidobacterium, animal bifidobacterium Bb-12, bifidobacterium bifidum R0071, bifidobacterium breve M-16V and bifidobacterium lactis HN-019, passing through an 80-100 mesh sieve, and mixing according to the above proportions to obtain.

6. Use of the probiotic compound preparation for improving constipation in children as claimed in any one of claims 1 to 3 in the preparation of health products, foods or medicines for treating and improving constipation in children.

Images